Search

Displaying results 3221 - 3230 of 4229 in total
  1. Drug

    Vosilasarm

    go.drugbank.com/drugs/DB13939
    Investigational

    RAD140 is an investigational selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and breast cancer.

  2. Drug

    GT-AS

    go.drugbank.com/drugs/DB17883
    Experimental

    GT-AS recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP.

    Synonyms: GT-AS
  3. Drug

    Rilvegostomig

    go.drugbank.com/drugs/DB18991
    Investigational

    Rilvegostomig is under investigation in clinical trial NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (Artemide-biliary01)).

  4. Drug

    Phenylalanine

    go.drugbank.com/drugs/DB00120
    ApprovedInvestigationalNutraceutical

    Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.

  5. Drug

    Phenelzine

    go.drugbank.com/drugs/DB00780
    ApprovedInvestigational

    Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA ap...

  6. Drug

    Leukotriene C4

    go.drugbank.com/drugs/DB08855
    Experimental

    It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue.

  7. Drug

    Urofollitropin

    go.drugbank.com/drugs/DB00094
    ApprovedVet approvedWithdrawn

    It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids.

  8. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    ]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as

  9. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    It is administered as a 1 hour intravenous infusion every 3 weeks.

  10. Drug

    Velafermin

    go.drugbank.com/drugs/DB06493
    Investigational

    Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract. … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated